Sequencing Therapy for Optimal Response in Mirikizumab (STORM)-study: A tertiary referral center study on patients with therapy-refractory ulcerative colitis.

ABSTRACT:

Background

Optimized drug sequencing is an emerging area of interest in the treatment of ulcerative colitis (UC). Comparative real-world data on treatment response to mirikizumab in a cohort with exposure to multiple biologic agents, particularly tumor necrosis factor (TNF)-naïve versus TNF-treated patients, remain limited. This study evaluated the therapeutic response to mirikizumab treatment in a cohort of patients with UC who were refractory to biologic therapy.

Methods

Consecutive patients with UC treated with mirikizumab between July 01, 2023, and May 31, 2025, at a tertiary university referral center were retrospectively analyzed. The primary endpoint was 12-week clinical remission. The secondary endpoints included clinical remission and biochemical remission between w

SUBMITTER: Kubesch A 

PROVIDER: S-EPMC12551913 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature